Please login to the form below

Not currently logged in
Email:
Password:

Stem cell

This page shows the latest Stem cell news and features for those working in and with pharma, biotech and healthcare.

ASH18: CAR-T and drugs give new options for multiple myeloma

ASH18: CAR-T and drugs give new options for multiple myeloma

dose chemo and undergone an autologous haematopoietic stem cell transplant (HSCT). ... Later today, Amgen will report additional data from a trial of AMG 420, its anti-BCMA bispecific T-cell engager (BiTE) antibody construct that in early readouts has

Latest news

More from news
Approximately 7 fully matching, plus 189 partially matching documents found.

Latest Intelligence

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    Raju Prasad says Bluebird can offer a compelling cost-effectiveness case for its treatment in beta thalassemia and sickle cell cases versus conventional stem cell treatment. ... Conventional stem cell transplants cost anywhere between $500, 000 and $1m,

  • Reaching the new influencers Reaching the new influencers

    Right now, we’re living through healthcare’s age of accelerations - as evidenced by advances in everything from biotechnology and stem cell research to machine learning and the advent (and approvals)

  • Can value-based healthcare take off and reach for the skies? Can value-based healthcare take off and reach for the skies?

    CAR-T cell therapy for children with B-cell ALL. ... way under the cost-effective price and significantly lower than the current standard of allogenic stem cell transplant that costs $500, 000-800, 000 in the first year with follow-up

  • Deal Watch January 2018

    Takeda moves in neurodegenerative diseases and stem cell therapy. Meanwhile Takeda, ranked 4. ... A few days later Takeda announced it was paying $628m (82% share price premium) to buy Belgian company TiGenix NV and its lead asset Cx601 (darvadstrocel),

  • Pharma deals continue to slide Pharma deals continue to slide

    425 (upfront 80). Calimmune (US). CSL (AU). Company acquisition. Preclinical haematopoietic stem cell therapy for sickle cell disease.

More from intelligence
Approximately 0 fully matching, plus 27 partially matching documents found.

Latest appointments

  • Industry appointments Industry appointments

    Rogerio Vivaldi leaves Bioverativ buyout to head up Sigilon. US-based biotech Sigilon aiming to deliver stem cell therapies for diabetes is getting a new leader. ... In the longer term, Hassan will lead research activities with the aim to expand

  • Weekly industry appointments Weekly industry appointments

    There, he is medicines development leader for adenosine deaminase deficiency (ADA-SCID) gene therapy Strimvelis – the first alternative medicine to stem cell transplant for the disease that’s bagged a regulatory ... be a global leader in the

  • Porterhouse Medical promotes Emma Conran Porterhouse Medical promotes Emma Conran

    Conran has served in medical writing positions at Porterhouse Medical since 2014 and prior to that she was a translational stem cell biology lecturer at King’s College London.

  • apceth Biopharma appoints Dusan Kosijer as CFO apceth Biopharma appoints Dusan Kosijer as CFO

    successful track record as one of the leading CDMOs for complex cell and gene therapy products. ... Moreover, Dusan’s experience will strongly promote our dynamic innovative strategy behind apceth’s unique proprietary pipeline of genetically modified

  • Dr Jay Stout moves from Merck to SanBio Dr Jay Stout moves from Merck to SanBio

    In this role, he is responsible for all production-related operations, including clinical cell preparation, final quality assurance and process development. ... He is perhaps the individual with the greatest experience in the world in manufacturing

More from appointments
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest from PMHub

  • Solaris Health looks at the gene therapy revolution

    As an example, in the case of Strimvelis (autologous CD34. cells transduced to express adenosine deaminase [ADA]), the first ex vivo stem cell gene therapy approved by the EMA (European Medicines ... 1. The ground-breaking treatment uses a virus to

  • Training the next generation of biotech leaders

    Novel technologies, coupled with programmes designed to drive cell and gene research and development, are ushering in a new era of therapies. ... Dr Ivan Wall is an expert in all things stem cell.

  • Biotech: it's a people business

    From Johnson &Johnson’s immunology treatments to Pfizer’s work on a stem cell-based remedy for age-related macular degeneration, pharma companies are quickly realising biotechnology is the future of

  • Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies

    Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the ... This, coupled with growing investment in the sector and an

  • Perspective on biotech leaders

    Download the magazine to find out about:. Commercialising cutting-edge stem cell therapies.

More from PMHub
Approximately 2 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics